Cyberknife Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver : Preliminary Results

Abstract EN

Purpose.

Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for local tumor control of primary and secondary malignancies of the liver.

We report on our updated experience with SBRT in patients with non-resectable tumors of the liver.

Methods.

Our first 17 consecutive patients (mean age 58.1 years) receiving SBRT for HCC (n=6), IHC (n=3), and LM (n=8) are presented.

Mean radiation dose was 34Gy delivered over 1–3 fractions.

Results.

Treated patients had a mean decrease in maximum pretreatment tumor diameter from 6.9±4.6 cm to 5.0±2.1 cm at three months after treatment (P<.05).

The mean total tumor volume reduction was 44% at six months (P<.05).

82% of all patients (14/17) achieved local control with a median follow-up of 8 months.

100% of patients with HCC (n=6) achieved local control.

Patients with surgically placed fiducial markers had no complications related to marker placement.

Conclusion.

Our preliminary results showed that SBRT is a safe and effective local treatment modality in selected patients with liver malignancies with minimal adverse events.

Further studies are needed to define its role in the management of these malignancies.